Skip to main content
. Author manuscript; available in PMC: 2014 May 29.
Published in final edited form as: Leukemia. 2010 Sep 16;24(12):2100–2109. doi: 10.1038/leu.2010.212

Figure 5. Effects of IAP inhibitor treatment and Abl inhibition, alone and combined, on the growth of BCR-ABL-expressing cells in vitro and in vivo.

Figure 5

(A) Approximately 3-day treatment of Ba/F3.p210 cells with LCL161, imatinib, or a combination of LCL161+imatinib. Calcusyn-derived combination indices are shown in Table 1. (B–D) In vivo bioluminescence imaging study. Male NCr nude mice were administered, via tail vein injection, approximately 800,000 Ba/F3-FLT3-ITD-luc+ cells. 32 mice were injected with 32D-p210-LucNeo cells and imaged 3 days later to determine tumor burden. Following randomization, mice were divided into 4 treatment groups (n=8). Treatments were carried out via oral gavage 5X per week for a total of 3 weeks. Mice were imaged every 4–8 days and time-to-sac was recorded. Mice were administered vehicle, nilotinib at 20mg/kg 1X daily, LCL161 at 100mg/kg 1X daily, or a combination of nilotinib+LCL161. (B) Plotted bioluminescence values for entire study. (C) Plotted bioluminescence values on Day 17 of treatment (p=0.0002, ANOVA). (D) Survival curve (p < 0.0001, ANOVA).